Cogane
Submitted by Marsha Miller Ph.D. on Sun, 12/06/2009
A new BDNF inducer enters the pipeline.
Drugs in the Queue
The Research Pipeline - taking drugs from the lab to the clinic
Submitted by Marsha Miller Ph.D. on Sun, 05/10/2009
Here's an overview of some of the more promising potential treatments moving through the research pipeline.
An Ampakine Upregulates BDNF
Submitted by Marsha Miller Ph.D. on Fri, 04/24/2009
An ampakine, a modulator of glutamate receptors, reduced memory and learning problems in HD mice.
CERE-120 (AAV-Neurturin) is neuroprotective in HD mouse model
Submitted by Marsha Miller Ph.D. on Thu, 04/23/2009
Neurturin. a neurotrophic factor, protected striatal and cortical neurons in an HD mouse model.
Disappointing results from a Phase II trial of CERE-120 for PD patients
Submitted by Marsha Miller Ph.D. on Thu, 04/23/2009
Neurturin, a neurotrophic factor, failed to yield meaningful improvement in PD patients.
Amarin files new drug application for AMR 101 in Europe
Submitted by Marsha Miller Ph.D. on Wed, 04/08/2009
Ethyl-EPA remains in the drug development pipeline.
The ACR-16 trial is enrolling participants
Submitted by Marsha Miller Ph.D. on Tue, 02/03/2009
An interview with lead investigator Dr. Karl Kieburtz.
Surprising Finding Points to Possible Treatment for Huntington Disease
Submitted by Marsha Miller Ph.D. on Sat, 01/31/2009
Drugs that increase the activity of PPAR-delta are added to the pipeline of potential treatments.
Long term antipsychotic use in elderly AD patients
Submitted by Marsha Miller Ph.D. on Fri, 01/09/2009
Elderly patients with AD on antipsychotic meds have a higher death rate.
Long term tetrabenazine use
Submitted by Marsha Miller Ph.D. on Thu, 01/01/2009
In an Italian study, TBZ improved chorea for most patients; over time the magnitude of the benefit declined somewhat.
